The Clinical Opening
In 1990, after five years of negotiation with the Food and Drug Administration, the Drug Enforcement Administration, the Scientific Advisory Board of the General Clinical Research Center at the University of New Mexico, and a hospital ethics committee that had never before approved the administration of a Schedule I psychedelic compound to human volunteers, the psychiatrist Rick Strassman became the first researcher in the United States to receive federal approval for clinical work with a classical hallucinogen since the programme-wide suspension of such research in the early 1970s. Over the subsequent five years, Strassman administered more than four hundred doses of N,N-dimethyltryptamine — the powerfully short-acting tryptamine now popularly known as DMT — to sixty healthy adult volunteers under rigorous clinical conditions. The dose-response work established the pharmacokinetic profile of intravenously administered DMT in humans, confirmed the safety of the substance at the doses used, and produced a body of phenomenological report that Strassman published in 2001 as DMT: The Spirit Molecule — a book that would become the most widely read clinical account of a psychedelic experience written for a lay audience in the post-prohibition era, and that would restart in English the serious public conversation about what these substances actually do.
The book was received as a curiosity by the scientific community Strassman had come from and as a revelation by the communities that had been waiting for someone with institutional credentials to report publicly what underground users of the compound had been describing to one another for decades. Strassman documented that the content of those experiences, reported by volunteers with no prior history of psychedelic use and no cultural framework for interpreting what they encountered, converged on a set of features that the standard neuropharmacological account of hallucinogen action could not predict and could not explain, extending far beyond the fact that DMT produced intense subjective experiences (which had been known since Stephen Szára’s Hungarian investigations of the late 1950s). The volunteers did not report diffuse mystical feeling-states or aesthetic distortion of the clinical environment. They reported, with startling consistency, being transported to a location that felt more real than the clinical room, and encountering in that location autonomous non-human entities that interacted with them communicatively.
Strassman was candid about the disconcertment this produced. He had designed the study as a conventional clinical pharmacology investigation. He had expected dose-dependent alterations of perception, affect, and cognition of a kind the psychiatric literature was already prepared to describe. The entity encounters — which occurred in roughly half of the high-dose sessions — were not what he had anticipated, and they forced upon him the methodological question of how the results of a clinical pharmacology study should be reported when the phenomenology consistently exceeds the categories the clinical literature possesses. Strassman’s own eventual interpretation, developed partly during the study and more fully in the years after its conclusion, involved a cautious endorsement of the possibility that DMT functioned as what he called a conduit — a pharmacological opening to dimensions of reality the unaltered brain is ordinarily incapable of perceiving — extending beyond the narrow sense of hallucinogen. This interpretation placed him outside the mainstream pharmacology of his training, and the Spirit Molecule book was written in part to explain, for a general audience, why a psychiatrist trained in the production-model orthodoxy had come to entertain an interpretation the production model could not accommodate.
The Phenomenology
The canonical Strassman high-dose session, as documented in his published protocols and subsequent reports, produced a reliable sequence. The volunteer, reclining in a darkened clinical room, received an intravenous bolus of approximately 0.4 mg per kilogram of body weight — a dose chosen for its reliable production of full psychedelic effect without the dysphoria that higher doses sometimes elicited. The subjective experience began within fifteen to thirty seconds of the injection. The volunteer reported rapidly losing contact with the clinical environment and being transported, apparently without bodily sensation of transition, to a location that was perceptually and affectively distinct from ordinary experience. The peak of the experience occurred between three and five minutes post-injection. By ten minutes the volunteer had generally returned to baseline. The entire arc of the most powerful altered state in known pharmacology was contained within a quarter hour.
The reported locations varied in surface detail but clustered around a consistent structural description. Volunteers described finding themselves in complex, geometrically articulated environments that exhibited colours and textures they had no prior experiential reference for. The environments were not perceived as dreamlike in the ordinary sense. They were reported as more vivid, more detailed, and more apparently real than the clinical room from which the volunteer had been transported. The volunteer’s cognitive functioning within the reported location was described as fully intact and in many cases heightened. Temporal experience was altered, with the subjective duration substantially exceeding the objective five to ten minutes of peak effect. Autobiographical identity was preserved. The volunteer knew who she was, where she had come from, and that she had received a pharmacological intervention; what was at issue was not her grip on personal identity but her assessment of where she now was.
The entities reported in roughly half of the high-dose sessions were described with striking consistency across volunteers who had no prior knowledge of one another’s reports. They were perceived as autonomous, intelligent, communicative, and clearly distinct from the volunteer’s own thoughts. They interacted with the volunteer in ways that felt interpersonal rather than hallucinated. Some were described as humanoid, some as machine-like, some as geometric configurations whose communication with the volunteer proceeded by means other than verbal language. Strassman noted that the reports resembled, in content and affective tone, published accounts of alien abduction experiences, near-death experiences, and certain classes of mystical encounter across traditions. The convergence across these independent phenomenological literatures was, he observed in the Spirit Molecule text, one of the most striking features of the data. The volunteers had not been instructed to look for entities. The clinical staff had not prompted entity-themed questions. The encounters arrived unbidden and were described in consistent detail by volunteers whose cultural frameworks varied widely.
The methodological question Strassman faced, and which he returned to repeatedly in his later writing, was whether the entity encounters should be interpreted as elaborate self-generated hallucinations produced by DMT-induced disinhibition of cortical networks ordinarily constrained by top-down processes, or whether they should be interpreted as perceptual encounters with something that was in some sense actually there. The production-model interpretation was available and had the advantage of consistency with the standard neuropharmacological account of how serotonin 5-HT2A receptor agonism alters visual and affective processing. It had the disadvantage of failing to account for several consistent features of the reports: the heightened rather than diminished clarity of cognition during the experience, the autonomy of the entities in a manner more characteristic of interpersonal encounter than of imagery, and the convergence across volunteers who had no shared cultural framework to generate the common features. Strassman did not claim to resolve the question. He claimed that the evidence was consistent with interpretations that the standard model was not prepared to accommodate, and that the refusal to consider such interpretations was itself a methodological position rather than a conclusion the data had forced.
Gallimore and the Engineered Encounter
Andrew Gallimore is a British neuroscientist and pharmacologist whose doctoral training was in receptor-level computational modelling of serotonergic signalling and whose post-doctoral work at the Okinawa Institute of Science and Technology Graduate University (OIST) focused on computational neurochemistry and 5-HT2A receptor function. Gallimore’s interest in DMT originated during his graduate work, when he became aware of Strassman’s reports and recognised that the phenomenology the volunteers described was not easily reconciled with what his receptor-level models predicted. His subsequent work, developed in a series of papers and in the 2019 monograph Alien Information Theory, proposed what is in effect an engineering response to the limitation Strassman’s clinical protocol had faced: the peak of the DMT experience lasts only a few minutes, and the volunteer returns to baseline before she has had adequate time to investigate the territory she has been transported to. Gallimore asked whether the duration could be extended, and whether, if it could, the investigation of the territory could proceed as a genuine empirical inquiry rather than as a brief incursion the volunteer was obliged to report on afterward.
The technical proposal Gallimore developed, in collaboration with the psychiatrist Rick Strassman — whose original 1994 blood-sampling data (Archives of General Psychiatry) provided the pharmacokinetic foundation — involved administering DMT through a continuous intravenous infusion calibrated to maintain a steady-state plasma concentration at the level Strassman’s work had established as producing full peak effect. The pharmacokinetic challenge was considerable. DMT has a half-life of roughly fifteen minutes in human plasma, is metabolised rapidly by monoamine oxidase, and produces tolerance at the receptor level over sufficiently long exposures. The infusion protocol Gallimore proposed, which came to be known in the subsequent literature as DMTx or extended-state DMT, required careful titration of the infusion rate to compensate for elimination and for receptor adaptation, and the development of pharmacokinetic models that could predict the plasma and brain concentrations throughout a session of hours rather than minutes. The engineering problem had been considered infeasible at the time Strassman’s original study was conducted. By the late 2010s, the advances in pharmacokinetic modelling, continuous infusion technology, and institutional capacity for extended psychedelic sessions made it, in Gallimore’s analysis, tractable for the first time.
The first successful extended-state DMT sessions were conducted in 2022 by Imperial College London’s Centre for Psychedelic Research under the direction of Chris Timmermann. The protocol maintained peak DMT effect for approximately thirty minutes — a sixfold increase over the duration Strassman’s bolus protocol had produced — and the preliminary results, published in 2023, confirmed that the phenomenological features Strassman had documented remained stable throughout the extended session. The volunteers reported being in a consistent environment that did not dissolve over the extended duration. They were able to perform cognitive tasks within that environment. The entities, when encountered, remained present across the extended window in a manner consistent with continuous interpersonal contact rather than with transient imagery. The engineering intervention did not change the phenomenology. It permitted the phenomenology to be investigated.
Gallimore’s theoretical framework, as developed in Alien Information Theory, proposed that DMT should be understood as modulating the parameters of the reducing-valve function Aldous Huxley had described in The Doors of Perception — the mechanism by which the brain constrains the bandwidth of consciousness to the narrow range compatible with embodied survival. On Gallimore’s reading, DMT relaxes the filter sufficiently that channels of information ordinarily inaccessible to waking awareness become, briefly, perceivable. These channels, he argued, carry content that has its own structure, its own apparent agents, and its own regularities — features that distinguish the DMT experience from dreams, hallucinations, and endogenously generated imagery. The inference he drew was that the content of the DMT experience ought to be investigated as though it referred to something rather than dismissed as though it could not. The extended-state protocol was, in this reading, an instrument for such investigation — the minimum equipment required to look at the territory for long enough to notice its features.
The Pineal Question
A secondary strand of Strassman’s work concerned the possibility that DMT is produced endogenously in the human brain. The compound had been identified in mammalian tissue since the 1960s. Strassman, drawing on the work of the neurobiologist Stephen Barker and others, proposed that the pineal gland might function as the primary site of DMT synthesis in humans, and that endogenous DMT might be released at moments of extreme physiological stress — birth, dying, profound meditation, severe trauma. This proposal was more speculative than the clinical phenomenology work, and Strassman presented it with appropriate caution in the Spirit Molecule book. The empirical case for endogenous DMT production was subsequently advanced by Barker et al. (2013), who detected DMT in living rat pineal dialysate, and decisively by Dean et al. (2019, Scientific Reports) — a study co-authored by Strassman himself — which demonstrated a cardiac-arrest DMT surge in rat brain at concentrations comparable to serotonin, norepinephrine, and dopamine. The Dean et al. finding confirmed endogenous DMT as a physiologically significant neurochemical rather than a trace metabolite. However, the same study complicated the pineal-specificity hypothesis: cortical DMT levels showed no significant difference between pineal-intact and pinealectomized rats, either at baseline or following cardiac arrest. The synthesis machinery — INMT mRNA detected via RNAscope in human cerebral cortex and hippocampus — is distributed across the brain, not concentrated in the pineal. The pineal may contribute, but the cortex appears to be the dominant source. This is more interesting, not less: DMT’s role in consciousness may be ongoing and distributed rather than pineal-secreted at threshold moments alone.
The hypothesis that endogenous pineal DMT release accompanies the dying process connects Strassman’s work directly to near-death experience phenomenology, and to the cross-tradition descriptions of the death threshold as a moment of altered perception. If the dying brain produces DMT at concentrations capable of modulating the reducing valve, then the near-death experience might be, in part, a pharmacological event — an endogenous entheogenic experience triggered by the specific physiological conditions of the terminal state. This is not the whole story, and Strassman was careful to note that it does not explain the veridical perception cases NDE researchers have documented. But it provides a biochemical substrate for the phenomenology in a way that the orthodox neuropharmacological literature had not supplied, and it ties the entheogenic territory to the dying territory in a manner that neither frame alone had been able to accommodate.
The Rendering-Model Reading
The rendering framework accommodates the DMT evidence in ways that the production model cannot. If consciousness is the substrate from which embodied experience is rendered, and the brain is the transducer through which the rendering occurs, then DMT is a pharmacological intervention that temporarily alters the parameters of the transducer in ways that permit rendering at frequencies the ordinary instrument does not access. The entities encountered are not, on this reading, necessarily generated by the DMT itself. They are encountered because the transducer, under DMT modulation, is briefly capable of rendering the content of frequency bands in which such entities exist. The territory is present. The ordinary instrument does not access it. The modified instrument does, for a few minutes. The extended-state protocol extends the window, and the engineering advance is one of the first genuinely novel instruments consciousness research has acquired for investigating territory the standard instruments cannot reach.
The convergence across the independent phenomenological literatures — DMT entity encounters, alien abduction reports, NDE contact narratives, shamanic entity encounters across traditions, the contact literature centered on the Nine — is, on the rendering reading, a natural consequence of the fact that these different routes are opening the transducer to overlapping portions of the same territory. They are not the same experiences. The routes differ; the durations differ; the affective tones differ; the specific features of the content vary. But the structural similarities across otherwise unconnected reports are striking enough to warrant the hypothesis that something consistent is being encountered by multiple methods, and the rendering model provides the structural explanation that the alternative — each route producing its own unconnected hallucinatory content that happens to resemble the other routes’ unconnected hallucinatory content — struggles to supply.
Terence McKenna‘s earlier reports of what he called the self-transforming machine elves — the autonomous, communicative, playful entities he described encountering reliably during smoked DMT experiences in the 1980s — are confirmed in structural outline by the Strassman clinical data and by the extended-state results. McKenna’s reports were dismissed as the eccentric phenomenology of an unusual observer whose enthusiasm for the substance might have shaped what he perceived. The subsequent clinical and extended-state data, produced under controlled conditions by volunteers with no prior exposure and by researchers with no stake in confirming McKenna’s claims, recover the same structural features the McKenna reports had described. The convergence, again, is the point. It does not prove that the entities are what they appear to be. It does establish that whatever they are, they are encountered with sufficient consistency across observers and methods that dismissing them as incidental to the pharmacology is no longer a responsible position.
Honest Assessment
The scientific state of the evidence about DMT is peculiar in that it is simultaneously robust and inconclusive. The pharmacology is well characterised; the subjective phenomenology is reliably reproducible; the safety profile under clinical conditions is established; the entity encounters occur with the frequency Strassman documented and have been confirmed in subsequent studies; the extended-state protocol has been validated. What remains unsettled is the interpretive question of what the experiences represent. The orthodox reading is that they are the outputs of disinhibited cortical networks responding to 5-HT2A agonism with content assembled from the volunteer’s cognitive and affective substrate. The non-orthodox reading, which Strassman entertained cautiously and Gallimore argues more directly, is that the experiences involve perceptual contact with something that exists independently of the volunteer’s brain and becomes perceptually accessible under the pharmacological conditions DMT produces. The evidence available at present is consistent with both readings. The choice between them depends substantially on prior commitments about what kinds of ontological entities one is willing to include in one’s model of the world.
What the Strassman and Gallimore work together have established beyond reasonable dispute is that the experiences are real, reproducible, and structurally consistent; that the phenomenology is not adequately described by the standard neuropharmacological vocabulary; and that the engineering advances required to investigate the territory more thoroughly are now within reach. The door Strassman opened in 1990 is held open longer, at present, than it has ever been held open in the history of formal consciousness research. What is behind the door remains the central unresolved question in the psychedelic literature, and the resolution will depend on whether the institutional structure of consciousness research is willing to take the territory seriously enough to continue looking at it with the instruments now available.
References
Cozzi, Nicolas V., et al. “Dimethyltryptamine and Other Hallucinogenic Tryptamines Exhibit Substrate Behavior at the Serotonin Uptake Transporter and the Vesicle Monoamine Transporter.” Journal of Neural Transmission, vol. 116, 2009, pp. 1591–1599.
Gallimore, Andrew R. Alien Information Theory: Psychedelic Drug Technologies and the Cosmic Game. Strange Worlds Press, 2019.
Gallimore, Andrew R., and Rick J. Strassman. “A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.” Frontiers in Pharmacology, vol. 7, 2016, p. 211.
Griffiths, Roland R., et al. “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.” Psychopharmacology, vol. 187, 2006, pp. 268–283.
Strassman, Rick J. DMT: The Spirit Molecule. Park Street Press, 2001.
Strassman, Rick J. “Human Hallucinogenic Drug Research: Regulatory, Clinical, and Ethical Issues.” NIDA Research Monograph, vol. 146, 1994, pp. 92–123.
Strassman, Rick J., et al. “Dose-Response Study of N,N-Dimethyltryptamine in Humans.” Archives of General Psychiatry, vol. 51, 1994, pp. 85–97.
Timmermann, Christopher, et al. “Human Brain Effects of DMT Assessed via EEG-fMRI.” Proceedings of the National Academy of Sciences, vol. 120, 2023.